Home › Maagkanker › Michigan › Detroit
Maagkanker klinische studies in Detroit, MI
16 studies voor Maagkanker zoeken deelnemers op locaties in en rond Detroit (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruterenGezonde vrijwilligers welkom
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
RekruterenGezonde vrijwilligers welkom
- Henry Ford Health Saint John Hospital, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma
RekruterenFase 3
- Henry Ford Health, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RekruterenFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RekruterenFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruterenFase 1
- Karmanos Cancer Institiute, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekruterenFase 1
- Henry Ford Cancer Institute, Detroit
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RekruterenFase 1/2
- Brigitte Harris Cancer Pavilion BHCP, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekruterenFase 1/2
- Karmanos Cancer Institute, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RekruterenFase 1/2
- Henry Ford Cancer Institute, Detroit
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
RekruterenFase 1
- Investigative Site #120, Detroit
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RekruterenFase 1
- Karmanos Cancer Institute, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RekruterenFase 1
- Henry Ford Health System, Detroit
Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
RekruterenFase 1
- Henry Ford Cancer-Detroit, Detroit
A Beta-only IL-2 ImmunoTherapY Study
RekruterenFase 1/2
- Karmanos Cancer Institute, Detroit
Maagkanker studies in andere steden
- Houston, TX42 studies
- Boston, MA32 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Baldwin Park, CA22 studies
- Los Angeles, CA22 studies
- Arlington, VA20 studies
- Dallas, TX19 studies
- San Antonio, TX19 studies
- St. Louis, MO18 studies
- Grand Rapids, MI18 studies
- Chicago, IL16 studies
Andere studies in Detroit
- Niet-kleincellige longkanker44 studies
- Borstkanker33 studies
- Kanker (alle vormen)29 studies
- Colorectale kanker26 studies
- Eierstokkanker26 studies
- Metastatische kanker24 studies
- Prostaatkanker22 studies
- Endometriumkanker21 studies
- Longkanker20 studies
- Multipel myeloom19 studies
- Plaveiselcelcarcinoom van hoofd en hals15 studies
- Acute myeloïde leukemie14 studies
Van ClinicalTrials.gov, gegevens opgehaald op 6 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.